Weight Loss
& GLP-1
Semaglutide, tirzepatide, and the new generation of weight-loss medication — without the marketing fog.
Provider reviews in this category.
LegUpRx Sublingual Semaglutide
$174/month, 503A compounded, all 50 states. The cheapest verified legal cash-pay GLP-1 in May 2026. Graded 8.5/10 across cost, intake, sourcing, screening.
Read the review →LegUpRx Injectable Tirzepatide
$499/month, 503A compounded, all 50 states. The dual GIP/GLP-1 mechanism of Mounjaro and Zepbound at roughly half the brand-name cash price. Graded 7.8/10 with the regulatory tail-risk caveats spelled out.
Read the review →More reviews in production.
Brand-name pathways (Wegovy via NovoCare, Zepbound via LillyDirect), competing compounded telehealth providers, and insurance-covered routes. Roughly one review per week.
Four dimensions,
on every provider.
Every review in this category answers the same four questions. Equal-weighted scoring, transparent methodology, updated when pricing or regulation shifts.
Total annual cost
We publish the all-in twelve-month math for every program — intake fee, monthly subscription, surcharges for compounded vs. brand-name, and shipping. The headline price is almost never the number you actually pay.
The 90-day clinical timeline
GLP-1 medications don't produce meaningful weight loss in week 4. They produce it in week 12. Most people quit at week 6, right before the slope of the curve steepens. We say so plainly.
Compounded vs. brand-name status
The FDA's April 30, 2026 proposal removes semaglutide, tirzepatide, and liraglutide from the 503B bulks list. We track which providers still offer compounded options legally and which have switched to brand-name.
Provider-by-provider intake honesty
Some intakes ask only the questions that gate prescription approval. Others ask the safety-relevant ones. We complete the intake at every provider we recommend and document the difference.
The Apothecary and MOMENT are the same brand — daily supplements and on-demand strips, no physician required.
How we grade.
Four dimensions, equal weight. Cost (total 12-month all-in), intake honesty (we complete it), sourcing transparency, and screening rigor.